IN8bio Presents Biologic Correlative Data from the INB-200 Phase 1 Trial in Newly Diagnosed Glioblastoma at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
06 11월 2023 - 10:00PM
IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage
biopharmaceutical company focused on innovative gamma-delta T cell
therapies, today presented new biological correlative data from the
ongoing Phase 1 clinical trial of INB-200 targeting newly diagnosed
glioblastoma multiforme (GBM) in a poster presentation at the
Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting.
Chemotherapy has remained a mainstay of solid
tumor treatment. Alkylating agents such as temozolomide (TMZ) can
directly kill chemotherapy-sensitive GBM cells but can also
sensitize chemotherapy resistant tumor cells to immune recognition
by upregulating stress-associated NKG2D ligands (NKG2DL) to drive
immunogenicity. Unfortunately, the lymphodepleting effects of
chemotherapy, such as TMZ, also kills T cells, and prevents an
effective immune response to these stress targets. IN8bio’s DeltEx
DRI gamma-delta T cells are designed to be resistant to
chemotherapy, allowing them to remain functional and be used in
combinations to create a strong synergistic tumor cell killing
impact.
“Gamma-delta T cells are important in immune
responses and their high levels are known to correlate with
improved survival outcomes. Efficient immune reconstitution is
pivotal for favorable outcomes in cancer patients. This new
analysis sheds light on how our DeltEx DRI gamma-delta T cell
approach may induce durable persistence and immune responses,” said
William Ho, Co-founder and CEO. “These important insights will help
inform the ongoing development of our DeltEx DRI therapies across a
variety of solid and hematological tumors.
These data demonstrate that the lymphodepleting
effects of chemotherapy results in a globally suppressed immune
system where the DeltEx DRI gamma-delta T cells can strengthen the
immune response and potentially broadly eliminate cancer cells.
Furthermore, conventional standard-of-care can act as a long-term
lymphodepleting agent, an important component for the development
of allogeneic and potentially ‘off-the-shelf’ cellular therapies.
In June 2023, IN8bio presented positive data from the Phase 1 study
of INB-200 in an oral presentation at the American Society of
Clinical Oncology (ASCO) 2023 Annual Meeting. The Company will
present updated patient, survival and enrollment data from the
study at the Society for Neuro-Oncology (SNO) Annual Meeting taking
place November 15-19, 2023.
About INB-200INB-200 is a
genetically modified autologous drug resistant immunotherapy (DRI)
product candidate for the treatment of solid tumors. This novel
platform utilizes genetic engineering to generate chemotherapy
resistant gamma delta T cells which can be administered
concurrently with standard-of-care treatment in solid tumors. This
is a powerful, synergistic treatment approach enabling gamma-delta
T cells to persist in the presence of chemotherapy, and maintain
their natural ability to recognize, engage and kill cancer
cells.
INB-200 is the first genetically engineered
gamma-delta T cell therapy to be administered to patients with
solid tumors and our initial indication is in GBM.
About IN8bio
IN8bio is a clinical-stage biopharmaceutical
company focused on the discovery, development and commercialization
of gamma-delta T cell product candidates for solid and liquid
tumors. Gamma-delta T cells are a specialized population of T cells
that possess unique properties, including the ability to
differentiate between healthy and diseased tissue. IN8bio’s DeltEx
platform employs allogeneic, autologous, iPSC and genetically
modified approaches to develop cell therapies, designed to
effectively identify and eradicate tumor cells.
IN8bio has initiated a Phase 2 trial of INB-400 in glioblastoma
(GBM) at multiple centers across the United States and has two
ongoing Phase 1 trials in solid and hematological tumors, including
INB-200 for GBM and INB-100 for patients with hematologic
malignancies undergoing transplantation. IN8bio also has a broad
portfolio of preclinical programs focused on addressing other
hematological and solid tumor cancers. For more information about
IN8bio and its programs, please visit www.IN8bio.com.
Forward Looking StatementsThis
press release may contain forward-looking statements made pursuant
to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. These statements may be identified by words
such as “aims,” “anticipates,” “believes,” “could,” “estimates,”
“expects,” “forecasts,” “goal,” “intends,” “may,” “plans,”
“possible,” “potential,” “seeks,” “will” and variations of these
words or similar expressions that are intended to identify
forward-looking statements, although not all forward-looking
statements contain these words. Forward-looking statements in this
press release include, but are not limited to, statements regarding
the development and continued progress and success of our
preclinical and clinical trials and programs and product
candidates; the timing of initiation, progress (including as to
enrollment) and scope of clinical trials, including for INB-100 and
INB-400; the success of gamma delta T cells as a treatment option
for patients with both solid and hematological cancers; IN8bio’s
progress towards and achievement of its goal of “Cancer Zero”; and
IN8bio’s ability to achieve anticipated milestones, including
expected data readouts from its trials, enrollment of additional
patients in its clinical trials, advancement of clinical
development plans and to develop new preclinical programs. IN8bio
may not actually achieve the plans, intentions or expectations
disclosed in these forward-looking statements, and you should not
place undue reliance on these forward-looking statements. Actual
results or events could differ materially from the plans,
intentions and expectations disclosed in these forward-looking
statements as a result of various factors, including: risks to site
initiation, clinical trial commencement, patient enrollment and
follow-up, as well as IN8bio’s ability to meet anticipated
deadlines and milestones; uncertainties inherent in the initiation
and completion of preclinical studies and clinical trials and
clinical development of IN8bio’s product candidates; the risk that
IN8bio may not realize the intended benefits of its DeltEx
platform; availability and timing of results from preclinical
studies and clinical trials; whether the outcomes of preclinical
studies will be predictive of clinical trial results; whether
initial or interim results from a clinical trial will be predictive
of the final results of the trial or the results of future trials;
the risk that trials and studies may be delayed and may not have
satisfactory outcomes; potential adverse effects arising from the
testing or use of IN8bio’s product candidates; expectations for
regulatory approvals to conduct trials or to market products;
IN8bio’s reliance on third parties, including licensors and
clinical research organizations; and other important factors, any
of which could cause our actual results to differ from those
contained in the forward-looking statements. These and other
factors are described in greater detail in the section entitled
“Risk Factors” in our Quarterly Report on Form 10-Q filed with the
Securities and Exchange Commission (SEC) on August 10, 2023, as
well as in other filings IN8bio may make with the SEC in the
future. Any forward-looking statements contained in this press
release speak only as of the date hereof, and IN8bio expressly
disclaims any obligation to update any forward-looking statements
contained herein, whether because of any new information, future
events, changed circumstances or otherwise, except as otherwise
required by law.
Company Contact:IN8bio, Inc.Patrick McCall+ 1
646.600.6GDT (6438)info@IN8bio.com
Investors & Media Contact: Argot
PartnersIN8bio@argotpartners.com
IN8bio (NASDAQ:INAB)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
IN8bio (NASDAQ:INAB)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024